Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Nemvaleukin alfa by Mural Oncology for Metastatic Breast Cancer: Likelihood of Approval
Nemvaleukin alfa is under clinical development by Mural Oncology and currently in Phase II for Metastatic Breast Cancer. According to...
Nemvaleukin alfa by Mural Oncology for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Nemvaleukin alfa is under clinical development by Mural Oncology and currently in Phase II for Recurrent Head And Neck Squamous...
Nemvaleukin alfa by Mural Oncology for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Nemvaleukin alfa is under clinical development by Mural Oncology and currently in Phase II for Head And Neck Squamous Cell...
Nemvaleukin alfa by Mural Oncology for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Nemvaleukin alfa is under clinical development by Mural Oncology and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction....
Nemvaleukin alfa by Mural Oncology for Solid Tumor: Likelihood of Approval
Nemvaleukin alfa is under clinical development by Mural Oncology and currently in Phase II for Solid Tumor. According to GlobalData,...
Nemvaleukin alfa by Mural Oncology for Hepatocellular Carcinoma: Likelihood of Approval
Nemvaleukin alfa is under clinical development by Mural Oncology and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData,...
Nemvaleukin alfa by Mural Oncology for Gastric Cancer: Likelihood of Approval
Nemvaleukin alfa is under clinical development by Mural Oncology and currently in Phase II for Gastric Cancer. According to GlobalData,...
Nemvaleukin alfa by Mural Oncology for Lymphoma: Likelihood of Approval
Nemvaleukin alfa is under clinical development by Mural Oncology and currently in Phase II for Lymphoma. According to GlobalData, Phase...
Nemvaleukin alfa by Mural Oncology for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
Nemvaleukin alfa is under clinical development by Mural Oncology and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell...
Nemvaleukin alfa by Mural Oncology for Soft Tissue Sarcoma: Likelihood of Approval
Nemvaleukin alfa is under clinical development by Mural Oncology and currently in Phase II for Soft Tissue Sarcoma. According to...
Nemvaleukin alfa by Mural Oncology for Renal Cell Carcinoma: Likelihood of Approval
Nemvaleukin alfa is under clinical development by Mural Oncology and currently in Phase II for Renal Cell Carcinoma. According to...
Nemvaleukin alfa by Mural Oncology for Chondrosarcoma: Likelihood of Approval
Nemvaleukin alfa is under clinical development by Mural Oncology and currently in Phase II for Chondrosarcoma. According to GlobalData, Phase...
Nemvaleukin alfa by Mural Oncology for Pancreatic Cancer: Likelihood of Approval
Nemvaleukin alfa is under clinical development by Mural Oncology and currently in Phase II for Pancreatic Cancer. According to GlobalData,...
Nemvaleukin alfa by Mural Oncology for Melanoma: Likelihood of Approval
Nemvaleukin alfa is under clinical development by Mural Oncology and currently in Phase II for Melanoma. According to GlobalData, Phase...
Nemvaleukin alfa by Mural Oncology for Colorectal Cancer: Likelihood of Approval
Nemvaleukin alfa is under clinical development by Mural Oncology and currently in Phase II for Colorectal Cancer. According to GlobalData,...
Nemvaleukin alfa by Mural Oncology for Non-Small Cell Lung Cancer: Likelihood of Approval
Nemvaleukin alfa is under clinical development by Mural Oncology and currently in Phase II for Non-Small Cell Lung Cancer. According...
Nemvaleukin alfa by Mural Oncology for Ovarian Cancer: Likelihood of Approval
Nemvaleukin alfa is under clinical development by Mural Oncology and currently in Phase II for Ovarian Cancer. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Alkermes's Nemvaleukin alfa?
Nemvaleukin alfa is a fusion protein commercialized by Alkermes, with a leading Phase III program in Fallopian Tube Cancer;Peritoneal Cancer;Epithelial...